NuVasive, Inc. (NUVA)
(Delayed Data from NSDQ)
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Why NuVasive (NUVA) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
NuVasive (NUVA) Q2 Earnings Meet Estimates, Margins Down
by Zacks Equity Research
NuVasive's (NUVA) second-quarter 2023 results reflect the robust performance of the U.S. Cervical business.
NuVasive (NUVA) Q2 Earnings Meet Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 0% and 1.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) Q1 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
NuVasive's (NUVA) strong sales across the U.S. Spinal Hardware and U.S. Surgical Support businesses instill optimism.
NuVasive (NUVA) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 14.63% and 3.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -87.50% and 2.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Is NuVasive (NUVA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
New Strong Buy Stocks for April 26th
by Zacks Equity Research
EGY, MSGS, NUVA, NWG and VCISY have been added to the Zacks Rank #1 (Strong Buy) List on April 26, 2022.
NUVA vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
NUVA vs. ABT: Which Stock Is the Better Value Option?
Are Investors Undervaluing Baxter International (BAX) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is NuVasive (NUVA) Down 15.9% Since Last Earnings Report?
by Zacks Equity Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NuVasive's (NUVA) Precice System Cleared for Pediatric Patients
by Zacks Equity Research
NuVasive (NUVA) receives FDA 510(k) clearance for using the Precice limb lengthening system for treating pediatric patients.
NuVasive (NUVA), GMED Merger Aids, Macro Woes Mar Growth
by Zacks Equity Research
According to NuVasive (NUVA), the combined company is set to have an advanced commercial scale and portfolio of clinically proven solutions.
Lantheus and NuVasive have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Lantheus and NuVasive have been highlighted as Zacks Bull and Bear of the Day.
Bear of the Day: NuVasive (NUVA)
by Kevin Cook
Softer results for spinal surgery innovator plus questionable merger have dropped estimates and shares
NuVasive (NUVA) Q4 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Inflationary costs, supply chain disruptions, volatility in foreign exchange rates and the persistent COVID-led impact hurt NuVasive's (NUVA) Q4 revenues.
NuVasive (NUVA) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of -12.24% and 1.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of -4.06% and 2.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) Suffers From Macro Headwinds, Price Issue
by Zacks Equity Research
NuVasive (NUVA) believes that its 2022 guidance is appropriately conservative, considering macroeconomic pressures on net sales and operating profit.
Why Is Medtronic (MDT) Down 2.4% Since Last Earnings Report?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NuVasive (NUVA) Q3 Earnings Beat Estimates, Guidance Cut
by Zacks Equity Research
The continued demand for NuVasive's (NUVA) Simplified Cervical Disc is encouraging.
NuVasive (NUVA) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 1.89% and 0.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Can Cigna's (CI) Q3 Earnings Beat on Evernorth Performance?
by Zacks Equity Research
The third-quarter results of Cigna (CI) are likely to reflect a rise in total medical customers.
NuVasive (NUVA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
NuVasive (NUVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.